---
title: "Zymeworks Inc. (ZYME.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ZYME.US.md"
symbol: "ZYME.US"
name: "Zymeworks Inc."
industry: "生物技術"
---

# Zymeworks Inc. (ZYME.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.zymeworks.com](https://www.zymeworks.com) |

## Company Profile

Zymeworks Inc.是一家臨床階段的生物技術公司，專注于發現、開發和商業化用于治療癌症、自身免疫和炎症性疾病（AIID）的生物治療藥物。其治療平台和全面整合的藥物開發引擎提供了靈活性和兼容性，以精確設計和開發高度差異化的基于抗體的治療候選藥物。公司的平台包括 Azymetric 多特異性抗體平台；藥物偶聯平台包括一套專有細胞毒素，涵蓋拓撲異構酶和微管抑制毒素、穩定連接子和偶聯技術；EFECT 平台，由一系列對抗體 Fc 區的修飾組成，能夠選擇性調節招募的細胞毒性免疫細胞，以用于各種治療應用；以及 ProTECT，一個腫瘤特異性免疫共刺激平台。其主要產品候選藥物包括 zanidatama...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:14.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 90 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 116.21% |  |
| Net Profit YoY | 44.20% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.39 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.73B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 134.48M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -18.46% | E |
| Profit Margin | -47.16% | E |
| Gross Margin | -28.84% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 116.21% | A |
| Net Profit YoY | 44.20% | B |
| Total Assets YoY | -18.45% | E |
| Net Assets YoY | -12.78% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -212.02% | D |
| OCF YoY | 116.21% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.30 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 19.43% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Zymeworks Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-18.46%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-47.16%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-28.84%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "116.21%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "44.20%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-18.45%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-12.78%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-212.02%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "116.21%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "19.43%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯維 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -27.03 | 521/603 | - | - | - |
| PB | 5.36 | 308/603 | 5.40 | 3.27 | 2.58 |
| PS (TTM) | 12.75 | 174/603 | 13.11 | 10.87 | 9.31 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-10T05:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 12 | 86% |
| Overweight | 2 | 14% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.91 |
| Highest Target | 42.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ZYME.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ZYME.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ZYME.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.